TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Gastroparesis Cardinal Symptom Index (GCSI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PVI variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first cycle toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: resectability rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Numerical Pain Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of adverse biliary events
Endpoint domain: Adverse events/effects
Primary endpoint: Calcaneal pitch angle (CPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic obliquity (PO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Cobb angle (CA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by Quebec Task Force Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to FOBT test kit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neointimal plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygenation failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Counting of suicidal events
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-Free Survival (PFS), Core Radiology Assessment
Endpoint domain: Mortality/survival
Primary endpoint: Progression-Free Survival (PFS), Investigator's Assessment
Endpoint domain: Mortality/survival
Primary endpoint: Mastery of breathlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Retained in the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Superiority to placebo measured by SEP diary question 3
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Ankylosing Spondylitis Disease Activity Index BASDAI 50 %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in TWSTRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent and Severity of Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Levels of Pemphigus Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive and Negative Predictive Value of PET Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptom-free heart blockages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to obtaining good Quality IVC images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD 14 and HLA-DR Expression Patterns on monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Changes From Baseline in Total Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores on the State-Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measurement of the relative quantity of titin protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the relative size of titin protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Freezing of Gait Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Microbial presence in the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Doppler results at 11-14 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Doppler results at 20-22 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of Time With Sensor Glucose Values Between 70 and 180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tear Evaporation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein Tear Break-up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who are recurrence-free
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients achieving 50% or greater reduction in wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Average Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Anxiety Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiver Transfer Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Lung function decline over the course of the study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality of life as assessed by the asthma quality of life questionnaire (AQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: dose-limiting toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of actually stopped or adjusted drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success rate of external cephalic version Twin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Marginal adaptation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minute Ventilation (MV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Timed 10 meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed up and Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical pregnancy as observed by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Frequency of patients requiring adjuvant chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change From Baseline in Lumbar Spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tracheal Intubation or Death Prior to Intubation
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events related to intra bone marrow islet infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent change of oxidant stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change of lipid oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinically significant changes in ECG, vital signs, physical examination findings, or clinical laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protocol completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CD prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Recurrence Rates of Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in WHSS at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracer kinetics as measured by distribution volume of radioligands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracer kinetics as measured by Standard Uptake Volume Ratio of radioligands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracer kinetics as measured by distribution volume of radioligands in off-target binding regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracer kinetics as measured by SUVR of radioligands in off-target binding regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 14-day Early Bactericidal Activity (EBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Management of biliary enteric anastomosis complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of epileptiform activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with cardiovascular dysfunction in childhood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with renal dysfunction in childhood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of participants with haematological anomalies persisting in childhood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with neurological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: structural changes of brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: functional changes of brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Suicide Assessment Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: screening uptake rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage change in Urine Protein-to-Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage change in Urine Albumin-to-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: EULAR Good Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Progression Defined by Change in Van Der Heijde-modified Total Sharp Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-tumoral and systemic immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Status of Participants on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of solicited local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of unsolicited local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-use subjective opinions regarding the hearing aids
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Past 90-day Alcohol Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Evidence of Illicit Substances in Urine Screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbial diversity of salivary microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bacteria identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of carbapenem susceptibility testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: clearance of high risk HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Accuracy in diagnosing posterior deep endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye drop instillation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Lung cancers
Endpoint domain: Mortality/survival
Primary endpoint: Number of nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of patients develop spontaneous expulsion of stone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Skin scraping test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Centre of pressure - AREA (mm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Centre of pressure - LENGTH (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time in secondary tasks (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Pain severity in temporomandibular joint disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free survival (DFS) rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free survival (DFS) rate at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free survival (DFS) rate at 48 months
Endpoint domain: Mortality/survival
Primary endpoint: Children's Depression Rating Scale - Revised (CDRS-R) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased Bleeding Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in Fibrosis by at least 1 stage without worsening of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Participants Reporting All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: AUC(0-t) of neratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) of neratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of neratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depression symptom score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: vestibular-evoked myogenic potentials (P13-N23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the curve for glucose and insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients given access to treatment with TheraSphere
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Evaluate patient experience with Therasphere
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Liver elasticity correlation with liver biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver elasticity evolution with viral kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of patients with ototoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Success of Treatment With Tiotropium According to Physician's Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of cases commencing hepatitis C treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: strength capacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of noncompliance to antimalarial treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative overhydration in liters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of pain symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-normalized area under the FEV1 percent change from pre-dose curve over 12 hours (nAUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time-normalized area under the FEV1 percent change from pre-dose curve over 24 hours (nAUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pain score ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with complete wound closure (100% re-epithelialisation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: High-resolution ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ≥ 4-Fold Rise in Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for Each Meningococcal Serogroup
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Response at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime PaCO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Amount of Time Spent Out of Bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Proptosis Response at Week 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral blood monocyte measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Side effects as determined by CTCAE scale
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Feeling of difficulty from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Estimates of effort from baseline
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in NASA Task Load Index from baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Time to complete unsolvable anagrams from baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Muscle effort tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Serum Bile Acid Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated hemoglobin loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in AUA Symptom Score Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inappropriate Left Ventricular Mass (LVM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and Local/Systemic Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of R- and S- warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics of R- and S- warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Alveolar Bone (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 year change in bone mineral density at the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 3 year change in coronary calcification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hand osteoarthritis score at final visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Concentration and attention scores at final visit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Osmotic regulation of AVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes